Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Stay away from companies that roll over the debt e.g. Bear Stearns
When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.
His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.
Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term
Spago Nanomedical AB Total Current Liabilities Related Terms
Spago Nanomedical AB Total Current Liabilities Historical Data
* Premium members only.
The historical data trend for Spago Nanomedical AB's Total Current Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spago Nanomedical AB Total Current Liabilities Chart
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.
Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.
What does a Total Current Liabilities of kr5.30 Mil mean?
Spago Nanomedical AB (OSTO:SPAGO) has a Total Current Liabilities of kr5.30 Mil as of Mar. 2026. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Spago Nanomedical AB and its competitors.
Is Spago Nanomedical AB's Total Current Liabilities too high?
Spago Nanomedical AB's current Total Current Liabilities is kr5.30 Mil. Overall, Spago Nanomedical AB has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spago Nanomedical AB's Total Current Liabilities compare to VRTX and REGN?
Spago Nanomedical AB's Total Current Liabilities of kr5.30 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Biotechnology company?
A good Total Current Liabilities depends on the Biotechnology industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Spago Nanomedical AB and its competitors. Spago Nanomedical AB's current Total Current Liabilities is kr5.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spago Nanomedical AB stock overvalued right now?
Based on GuruFocus' analysis, Spago Nanomedical AB (OSTO:SPAGO) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.03, compared to a current price of kr0.11 — trading 278.3% above its estimated fair value. The current Total Current Liabilities is kr5.30 Mil. Spago Nanomedical AB's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Spago Nanomedical AB (OSTO:SPAGO), the current Total Current Liabilities is kr5.30 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Spago Nanomedical AB (OSTO:SPAGO) Overvalued in 2026?
Based on GuruFocus' analysis, Spago Nanomedical AB stock appears to be overvalued.
The current stock price of kr0.11 is trading 278.3% above its estimated GF Value™ of kr0.03.
GuruFocus considers Spago Nanomedical AB to be Significantly Overvalued.
Key valuation signals for OSTO:SPAGO:
Total Current Liabilities: kr5.30 Mil
GF Value™: kr0.03 vs. price of kr0.11 (278.3% above fair value)
No single metric tells the full story. See the OSTO:SPAGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spago Nanomedical AB is a nanomedicine company in the field of cancer diagnosis and treatment. The company's product includes SpagoPix and Tumorad. The SpagoPix product aims to improve cancer diagnosis with magnetic resonance imaging through the previous detection of tumors and metastases. The Tumorad products focus on the development of a completely new form of radionuclide therapy for tumor-selective radiation therapy of cancer. The company's development projects are based on a platform of polymeric materials with various properties for the precise diagnosis and treatment of life-threatening and debilitating diseases.
34GF Score
Get the complete analysis for OSTO:SPAGO
Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:SPAGO has been successfully added to your 
